BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14998856)

  • 21. Expression of bone morphogenetic proteins in giant cell tumor of bone.
    Kudo N; Ogose A; Ariizumi T; Kawashima H; Hotta T; Hatano H; Morita T; Nagata M; Siki Y; Kawai A; Hotta Y; Hoshino M; Endo N
    Anticancer Res; 2009 Jun; 29(6):2219-25. PubMed ID: 19528484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro expression of the plasminogen activators and urokinase type plasminogen activator receptor (u-PAR) in the pig oviduct.
    Roldán-Olarte M; García DC; Jiménez-Díaz M; Valdecantos PA; Miceli DC
    Anim Reprod Sci; 2012 Dec; 136(1-2):90-9. PubMed ID: 23103014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Histogenesis of giant cell tumors].
    Wuelling M; Engels C; Jesse N; Werner M; Kaiser E; Delling G
    Pathologe; 2002 Sep; 23(5):332-9. PubMed ID: 12376858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiles of fibrinolytic components in nasal mucosa.
    Sejima T; Madoiwa S; Mimuro J; Sugo T; Ishida T; Ichimura K; Sakata Y
    Histochem Cell Biol; 2004 Jul; 122(1):61-73. PubMed ID: 15197554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
    Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
    Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
    Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
    Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients].
    Xiao W; Tong WL; Ma DD
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Nov; 29(11):723-6. PubMed ID: 17327049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
    Herouy Y; Aizpurua J; Stetter C; Dichmann S; Idzko M; Hofmann C; Gitsch G; Vanscheidt W; Schöpf E; Norgauer J
    J Cutan Pathol; 2001 Jul; 28(6):291-7. PubMed ID: 11401675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
    Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
    Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
    Quax PH; de Bart AC; Schalken JA; Verheijen JH
    Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
    Van den Eynden GG; Van Laere SJ; Van der Auwera I; Trinh XB; Van Marck EA; Dirix LY; Vermeulen PB
    Int J Cancer; 2009 Sep; 125(6):1494-6. PubMed ID: 19536843
    [No Abstract]   [Full Text] [Related]  

  • 37. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
    Pyke C; Kristensen P; Ralfkiaer E; Grøndahl-Hansen J; Eriksen J; Blasi F; Danø K
    Am J Pathol; 1991 May; 138(5):1059-67. PubMed ID: 1850957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells.
    Glass WF; Kreisberg JI; Troyer DA
    Am J Physiol; 1993 Mar; 264(3 Pt 2):F532-9. PubMed ID: 8384415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.